Ken Griffin Biotechnology

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
NKTR
Nektar Therapeutics
PUT
$18,000
14.1K
Q2 2024
Added 117.77%
OCUP
Ocuphire Pharma, Inc.
CALL
$18,000
14.1K
Q3 2024
Added 515.82%
TLSA
Tiziana Life Sciences LTD
CALL
$18,000
19.2K
Q3 2024
New holding
ACXP
Acurx Pharmaceuticals, Inc.
CALL
$17,000
9.2K
Q2 2024
New holding
IPSC
Century Therapeutics, Inc.
PUT
$17,000
10.2K
Q3 2024
Reduced 59.07%
CGEN
Compugen LTD
CALL
$17,000
9.4K
Q3 2024
Added 15224.61%
ARMP
Armata Pharmaceuticals, Inc.
PUT
$16,000
7K
Q3 2024
Reduced 52.67%
BTAI
Bio Xcel Therapeutics, Inc.
PUT
$16,000
27.7K
Q1 2024
Added 662.53%
CTXR
Citius Pharmaceuticals, Inc.
PUT
$16,000
32.1K
Q2 2024
New holding
ELEV
Elevation Oncology, Inc.
PUT
$16,000
27.6K
Q2 2024
Reduced 97.44%
NKTR
Nektar Therapeutics
CALL
$16,000
12.8K
Q2 2024
Added 117.77%
TARA
Protara Therapeutics, Inc.
CALL
$16,000
9K
Q3 2024
Added 2.28%
ALLO
Allogene Therapeutics, Inc.
CALL
$15,000
5.4K
Q3 2024
Added 105.99%
CRDF
Cardiff Oncology, Inc.
CALL
$15,000
5.9K
Q3 2024
Reduced 9.41%
KOD
Kodiak Sciences Inc.
PUT
$15,000
5.8K
Q3 2024
New holding
KURA
Kura Oncology, Inc.
PUT
$15,000
800
Q3 2024
Added 17.36%
TRVI
Trevi Therapeutics, Inc.
PUT
$15,000
4.5K
Q3 2024
New holding
IPSC
Century Therapeutics, Inc.
CALL
$14,000
8.7K
Q3 2024
Reduced 59.07%
DSGN
Design Therapeutics, Inc.
PUT
$14,000
2.7K
Q3 2024
Added 88.93%
RGLS
Regulus Therapeutics Inc.
PUT
$14,000
9.3K
Q3 2024
New holding
XFOR
X4 Pharmaceuticals, Inc
PUT
$14,000
22.2K
Q2 2024
Reduced 98.9%
ATOS
Atossa Therapeutics, Inc.
PUT
$13,000
8.6K
Q3 2024
Reduced 19.65%
BTAI
Bio Xcel Therapeutics, Inc.
CALL
$13,000
22.2K
Q1 2024
Added 662.53%
FGEN
Fibrogen Inc
PUT
$13,000
34.5K
Q3 2024
Added 128.26%
IMMX
Immix Biopharma, Inc.
CALL
$13,000
8.9K N/A
ENOB
Enochian Biosciences Inc
PUT
$13,000
3K
Q4 2023
Added 50.32%
ALVR
Allovir, Inc.
CALL
$12,000
14.9K
Q3 2024
Reduced 21.51%
ALXO
Alx Oncology Holdings Inc
PUT
$12,000
7K
Q2 2024
Reduced 94.45%
BYSI
Beyond Spring Inc.
CALL
$12,000
5.3K
Q2 2023
Reduced 44.76%
CLLS
Cellectis S.A.
CALL
$12,000
5.9K
Q3 2024
Added 3.46%
DSGN
Design Therapeutics, Inc.
CALL
$12,000
2.3K
Q3 2024
Added 88.93%
FATE
Fate Therapeutics Inc
CALL
$12,000
3.7K
Q3 2024
Reduced 4.59%
MNOV
Medicinova Inc
PUT
$12,000
6K
Q3 2024
Reduced 92.15%
LVTX
Lava Therapeutics Nv
CALL
$11,000
6.9K
Q3 2024
Reduced 74.31%
TNGX
Tango Therapeutics, Inc.
PUT
$11,000
1.5K
Q3 2024
Added 118.72%
ATHA
Athira Pharma, Inc.
CALL
$10,000
23.6K
Q2 2024
Reduced 50.65%
AUTL
Autolus Therapeutics PLC
CALL
$10,000
2.8K
Q3 2024
Reduced 42.37%
CUE
Cue Biopharma, Inc.
CALL
$10,000
14.4K
Q2 2024
Reduced 43.05%
KZR
Kezar Life Sciences, Inc.
CALL
$10,000
13.8K
Q3 2024
Reduced 49.2%
PRQR
Pro Qr Therapeutics N.V.
PUT
$10,000
5.7K
Q3 2024
Added 373.6%
RLAY
Relay Therapeutics, Inc.
CALL
$10,000
1.5K
Q3 2024
Added 150.09%
ACET
Adicet Bio, Inc.
PUT
$9,000
6.7K
Q3 2024
Reduced 91.6%
CTMX
Cytom X Therapeutics, Inc.
PUT
$9,000
8.3K
Q3 2024
Reduced 35.89%
KRON
Kronos Bio, Inc.
CALL
$9,000
9.3K
Q3 2024
Reduced 61.73%
ORMP
Oramed Pharmaceuticals Inc.
CALL
$9,000
4K
Q3 2024
New holding
PBYI
Puma Biotechnology, Inc.
PUT
$9,000
3.7K
Q3 2024
Reduced 40.77%
TBPH
Theravance Biopharma, Inc.
PUT
$9,000
1.2K
Q3 2024
Reduced 3.88%
GHRS
Gh Research PLC
PUT
$8,000
1.2K
Q3 2024
Added 36.97%
OMGA
Omega Therapeutics, Inc.
PUT
$8,000
7K
Q3 2024
Reduced 100.0%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email